16:59:02 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-11-22 Kvartalsrapport 2024-Q3
2024-08-30 Kvartalsrapport 2024-Q2
2024-05-24 Kvartalsrapport 2024-Q1
2024-05-17 Årsstämma 2024
2024-03-22 Bokslutskommuniké 2023
2024-01-26 Extra Bolagsstämma 2024
2023-11-01 Kvartalsrapport 2023-Q3
2023-08-31 Kvartalsrapport 2023-Q2
2023-05-25 Kvartalsrapport 2023-Q1
2023-04-14 Ordinarie utdelning CMH 0.00 SEK
2023-02-28 Bokslutskommuniké 2022
2022-12-13 Extra Bolagsstämma 2022
2022-11-18 Kvartalsrapport 2022-Q3
2022-08-30 Kvartalsrapport 2022-Q2
2022-05-27 Kvartalsrapport 2022-Q1
2022-04-26 Ordinarie utdelning CMH 0.00 SEK
2022-04-25 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-10-25 Kvartalsrapport 2021-Q3
2021-10-05 Extra Bolagsstämma 2021
2021-08-30 Kvartalsrapport 2021-Q2
2021-05-27 Kvartalsrapport 2021-Q1
2021-04-16 Ordinarie utdelning CMH 0.00 SEK
2021-04-15 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-11-20 Kvartalsrapport 2020-Q3
2020-08-18 Extra Bolagsstämma 2020
2020-08-07 Kvartalsrapport 2020-Q2
2020-04-29 Kvartalsrapport 2020-Q1
2020-04-24 Ordinarie utdelning CMH 0.00 SEK
2020-04-23 Årsstämma 2020
2020-02-28 Bokslutskommuniké 2019
2019-11-11 Kvartalsrapport 2019-Q3
2019-08-30 Kvartalsrapport 2019-Q2
2019-05-24 Kvartalsrapport 2019-Q1
2019-05-10 Ordinarie utdelning CMH 0.00 SEK
2019-05-09 Årsstämma 2019
2019-02-28 Bokslutskommuniké 2018
2018-11-16 Kvartalsrapport 2018-Q3
2018-08-31 Kvartalsrapport 2018-Q2
2018-05-25 Kvartalsrapport 2018-Q1
2018-04-27 Ordinarie utdelning CMH 0.00 SEK
2018-04-26 Årsstämma 2018
2018-02-28 Bokslutskommuniké 2017
2017-10-31 Kvartalsrapport 2017-Q3
2017-08-31 Kvartalsrapport 2017-Q2
2017-04-28 Kvartalsrapport 2017-Q1
2017-04-20 Ordinarie utdelning CMH 0.00 SEK
2017-04-19 Årsstämma 2017
2017-02-10 Bokslutskommuniké 2016

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Chordate Medical Holding är ett medicintekniskt bolag som har utvecklat, patenterat och CE-märkt en nervmodulerande behandlingsteknik för kronisk migrän och kronisk nästäppa (rinit), Kinetic Oscillation Stimulation (K.O.S). Bolaget säljer sina produkter till behandlande kliniker på utvalda europeiska marknader, Israel samt Saudiarabien, med målsättningen att öka närvaron på den globala marknaden.
2023-07-03 08:30:00

During The German Migraine and Headache Society's congress in Berlin, Dr. Tim P. Jürgens presented a case study from Chordate's migraine study. The case study accounts for one of the participating patients, a 45-year-old woman, whose days with migraines decreased significantly, from 18 to 8 days per month, with the help of K.O.S. The positive effect of the K.O.S. treatment lasted for four months without further treatment sessions.

“The case study is a good example of a migraine patient who, for various reasons, cannot medicate with drugs typically prescribed for chronic migraines, and who experiences a very positive effect from K.O.S. A reduction from 18 to 8 migraine days per month, combined with a four-month sustained effect, is a significant positive outcome. It demonstrates the great potential of K.O.S. as a new treatment option for individuals suffering from chronic migraines and who do not respond to other existing treatments," says Jan Hermansson, Clinical Research & Medical Director at Chordate Medical, who was present in Berlin.

The case study was authored by Florian Rimmele together with Tim P. Jürgens and Peter Kropp at the Department of Neurology, Headache Center North-East, University Medical Center Rostock. Below is an excerpt from the case study:

A 45-year-old female patient with a long history of chronic migraine with visual auras presented to our headache center. In addition to systemic mastocytosis with evidence of a KIT-D816V mutation, the patient suffers from bronchial asthma, recurrent depression, and anxiety disorder. On average, the patient had migraine on 18 days/month. Due to mastocytosis and allergic reaction to multiple substances, acute medication was only possible with tramadol, which showed only moderate effect. The established medicinal migraine prophylactics could not be used because of various contraindications; the patient reacted allergically to the considered amitriptyline and also the multiple injections of a prophylaxis with onabotulinumtoxinA are contraindicated in mastocytosis.

The patient received kinetic oscillatory stimulation (K.O.S.) in a double-blind, randomized placebo-controlled trial. Over 6 weeks, weekly stimulation of 10 minutes per nostril was given, under which the migraine improved very well and a reduction to an average of 8 migraine days/month was achieved. The patient reported no side effects during the stimulation therapy. After completion of the study and unblinding, the patient could be assigned to the test (verum) group. The improvement effect lasted for 4 months.

Conclusion
In this particular case, established migraine prophylactic medication was not possible in a patient with chronic migraine, due to her other medical conditions, especially systemic mastocytosis. K.O.S., which was performed as part of a study, proved to be a well-tolerated and long-lasting prophylactic.